tbuckley/cabot-search huggingface dataset:
Abstract 16555: Angiotensin II Directly Induces Mitochondrial Dysfunction and Atrophy in the Skeletal Muscle
Authors: Tomoyasu Kadoguchi, Shintaro Kinugawa, Arata Fukushima, Takaaki Furihata, Tadashi Suga, Shingo Takada, Wataru Mizushima, Masato Kudo, Junichi Matsumoto, Masaya Tsuda, Mikito Nishikawa, Takashi Yokota, Shoji Matsushima, Koichi Okita, Hiroyuki Tsutsui
Journal: Circulation (2014)

Background: Skeletal muscle abnormalities such as mitochondrial dysfunction, fiber type transition, and atrophy are the main cause of reduced exercise capacity observed in various diseases such as diabetes mellitus and heart failure. Renin-angiotensin system (RAS) was activated in the skeletal muscle in these conditions. We thus hypothesized that angiotensin II (Ang II) could directly induce skeletal muscle abnormalities. Methods and Results: Ang II (1000ng/kg/min, n=8) or vehicle (saline, n=8) was administrated into male C57BL/6J mice (10-12 week of age) via subcutaneously implanted osmotic minipumps for 4 weeks. Ang II significantly decreased body weight (26.6±0.3 vs. 27.6±0.3 g, p&lt;0.05) and hind limb skeletal muscle weight compared with vehicle at 4 weeks (159±2 vs. 166±2 mg, p&lt;0.05). It also decreased myocyte cross-sectional area in the skeletal muscle at 4 weeks (1869±29 vs. 2233±46 μm2, p&lt;0.05). Muscle RING finger-1 and atrogin-1, the markers of protein degradation, were significantly increased in the skeletal muscle tissue from Ang II at 4 weeks by 133% and 102%, respectively (p&lt;0.05). In addition, cleaved caspase-3 and TUNEL positive cells were significantly increased in Ang II at 4 weeks by 2.5 and 1.4-folds, respectively (p&lt;0.05). Citrate synthase (1 week, 121±4 vs. 162±9; 4 weeks, 117±7 vs. 152±4 nmol/min/mg protein), complex I (1 week, 264±27 vs. 396±30; 4 weeks, 281±21 vs. 400±30 nmol/min/mg protein) and complex III (1 week, 321±33 vs. 508±49; 4 weeks, 347±30 vs. 503±43 nmol/min/mg protein) activities were significantly decreased in mitochondria isolated from skeletal muscle from Ang II at 1 and 4 weeks (all p&lt;0.05). NADH staining revealed that type I fiber decreased by 31% and type IIb fiber increased by 38% in Ang II at 1 week. The work (16±1 vs. 27±3 J, p&lt;0.05) and run distance (359±18 vs. 589±59 m, p&lt;0.05) evaluated by treadmill test significantly decreased in Ang II at 4 weeks. An administration of Ang II for 1 week also induced mitochondrial dysfunction, fiber type shift, and protein degradation, but did not skeletal muscle atrophy. Conclusion: Ang II could directly induce the reduction of exercise tolerance in association with the abnormalities in skeletal muscle function and structure.
Re-treatment with Tositumomab and Iodine I 131 Tositumomab in patients with non-Hodgkin lymphoma who had previously responded to Tositumomab and Iodine I 131 Tositumomab
Authors: Kaminski M, Radford Ja, Gregory S, Leonard J, Knox S, Kroll S, R Wahl
Journal: Journal of Clinical Oncology (2005)

PURPOSE To study efficacy and safety of re-treatment with I-131 tositumomab in patients with low-grade, follicular, or transformed low-grade B-cell lymphoma who relapsed following a response to I-131 tositumomab. PATIENTS AND METHODS A prior response >/= 3 months to I-131 tositumomab was required. The single therapeutic dose following a dosimetric dose was adjusted to give the same total body dose (in Gy) as that used for the original dose, or was attenuated if the platelet count was less than 150,000 per mm(3) or if the prior treatment resulted in grade 4 cytopenias lasting longer than 7 days. Results Of 32 patients enrolled, 28 completed the therapeutic dose. A median of four therapies were given before re-treatment. Eighteen (56%) of 32 patients had a complete or partial response (median duration, 15.2 months); eight (25%) had a complete response (median duration, 35 months). Five continue in response from 1.8 to 5.7 years, with a median follow-up of 35 months. The overall median response duration was not significantly different for the two treatments, with no clinical factors predicting response or its duration. Ten of 18 re-responders had longer responses with re-treatment, with five having responses >/= 1.5 years longer. Grade 3/4 neutropenia and thrombocytopenia occurred in 50% and 43% of patients, respectively, similar to initial treatment. Antimouse antibodies developed in 10% of patients, and 12% developed elevated serum thyroid-stimulating hormone. Six patients were diagnosed with second malignancies, including four patients who developed myelodysplastic syndrome (one who had not received the therapeutic dose) and one with acute myelogenous leukemia. CONCLUSION Re-treatment with I-131 tositumomab following a previous response can produce second responses that can be durable.
Abstract 843: Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination
Authors: Philip M. Tedeschi, Yamini K. Kathari, Iqra Farooqi, Joseph R. Bertino
Journal: Cancer Research (2014)

Abstract In T-cell acute lymphoblastic leukemia (ALL), the genes CDKN2A (p16 and p14) and MTAP are homozygously co-deleted, with a frequency of ∼35 %. MTAP cleaves the natural substrate, 5′-deoxy-5′-methylthioadenosine, to adenine and 5-methylthioribose-1-phosphate, which are converted to adenine nucleotides and methionine. Cells lacking MTAP are unable to salvage adenine through this pathway and rely on the de novo pathway for purine synthesis. This variation between normal MTAP+ cells and tumor MTAP-/- cells led to several studies showing that MTAP -/- cells are more sensitive to inhibitors of de novo purine synthesis. Pralatrexate (PDX) is a second generation antifolate that targets dihydrofolate reductase and via conversion to polyglutamylates, inhibits de novo purine synthesis. 6-Thioguanine (6TG), an antimetabolite analog of guanine, also target de novo purine synthesis. MTAP-deficient ALL cells should be more sensitive to these agents, remarkably so in combination. We tested single agent PDX and 6TG as well as a combination treatment in MTAP+ (Molt4) and MTAP-/- (CEM) ALL xenografts. CEM xenografts were more sensitive to PDX treatment than MOLT4 xenografts. CEM xenografts were also much more sensitive to 6TG, while Molt4 xenografts were resistant to 6TG. Early results of the combination of PDX and 6TG in vivo show promise as an effective therapy of MTAP-/- T-cell ALL. Citation Format: Philip M. Tedeschi, Yamini K. Kathari, Iqra Farooqi, Joseph R. Bertino. Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 843. doi:10.1158/1538-7445.AM2014-843
<i>Escherichia coli</i> O157 and <i>Salmonella</i> Infections Associated with Sprouts in California, 1996–1998
Authors: Janet C. Mohle-Boetani, Jeff A. Farrar, S. Benson Werner, Dzovag Minassian, Ray Bryant, Sharon Abbott, Laurence Slutsker, Duc J. Vugia
Journal: Annals of Internal Medicine (2001)

Background: In California, from 1996 through 1998, more than 50% of multicounty outbreaks with confirmed food vehicles were related to alfalfa or clover sprouts. Objective: To summarize investigations of sprout-associated outbreaks. Design: Matched case–control studies. Setting: California. Patients: Outbreak-associated patients and matched population controls. Measurements: Matched odds ratios and 95% CIs; traceback and environmental investigations of sprout and seed growers; and pulsed-field gel electrophoresis of isolates from patients, sprouts, and seeds. Results: Five sprout-associated outbreaks of salmonellosis and one outbreak of infection with nonmotile Shiga toxin–producing Escherichia coli O157 occurred. Six hundred patients had culture-confirmed disease, and two died. It is estimated that these outbreaks caused 22 800 cases of gastrointestinal illness or urinary tract infection. In the case–control studies, odds ratios for the association between illness and alfalfa sprout consumption ranged from 5.0 to ∞ (all were statistically significant). Three sprout growers were implicated, and each was associated with two outbreaks. Outbreak strains of Salmonella were isolated from sprouts supplied by two sprout growers and from seeds used by the third sprout grower. Conclusions: As currently produced, sprouts can be a hazardous food. Seeds can be contaminated before sprouting, and no method can eliminate all pathogens from seeds. Seed and sprout growers should implement measures to decrease contamination. The general public should recognize the risks of eating sprouts, and populations at high risk for complications from salmonellosis or E. coli O157 infection should avoid sprout consumption. *For members of the Investigation Team, see Appendix.
Determination of Levels of Carcinoembryonic Antigen and Nonspecific Cross-Reacting Antigen in the Sera of Neonatal Infants: Brief Communication
Authors: S. von Kleist, S. Troupel, M. King, P. Burtin
Journal: JNCI Journal of the National Cancer Institute (1977)

Seventy-eight sera from neonatal infants, born at full term or prematurely, were studied for their carcinoembryonic antigen (CEA) and nonspecific cross-reacting antigen (NCA) concentrations, which were compared to the normal adult concentrations. The levels of CEA in the sera were significantly higher in newborns than in adults: 9.05 ng CEA/ml in newborns as compared to 2.5 ng CEA/ml in adults (P=O.001). The levels of NCA in the sera were also higher in newborns: 164 ng NCA/ml in newborns as compared to 130 ng NCA/ml in adults. This difference in NCA levels was not significant, although 80% of the newborns had increased values (>130 ng/ml). Whether the infant was born at full term or prematurely and whether the infant was a boy or girl had no statistically significant influence on the concentration of the CEA and the NCA in the infant.
Abstract 819: A novel small molecule cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to treatment with gemcitabine
Authors: Mi Young Yang, Young Bok Lee, Deog Joong Kim, Chang-Ho Ahn, Joel Kaye, Tania Fine, Rina Kashi, Osnat Ohne
Journal: Cancer Research (2014)

Abstract RX-3117 (fluorocyclopentenylcytosine) is a novel small-molecule chemotherapeutic agent that belongs to the class of cytotoxic antimetabolite cytidine analogs. Cytidine analogs, including gemcitabine, have been widely used for the treatment of various types of cancer, both hematologic as well as solid. However, despite the success of gemcitabine, there is no oral formulation of gemcitabine and drug resistance is common. Thus, RX-3117 was synthesized as a oral formulation to overcome gemcitabine resistance with a better pharmacologic profile. In this study, the efficacy of RX-3117 was examined in 12 different human tumor (colon, non-small cell lung, small cell lung, pancreatic, renal, ovarian and cervical) xenograft models, grown subcutaneously in athymic nude mice. Not only has RX-3117 demonstrated potent efficacy in several cancer xenograft models but also oral treatment with RX-3117 results in dose-dependent tumor growth inhibition (TGI), even in tumors that are only moderately sensitive or resistant to gemcitabine. In the Colo-205, H460, H69 and CaSki models, gemcitabine treatment resulted in 28%, 14%, 25%, and 0% TGI, respectively, whereas oral treatment with RX-3117 induced 93%, 91%, 62%, and 66% TGI, respectively. This indicates that RX-3117 may have the potential to be used for the treatment of tumors that do not respond to gemcitabine. In order to extend the results established in cell line xenograft models, and to test efficacy in a potentially more clinically relevant system, RX-3117 was evaluated in a single primary low passage human pancreatic Tumorgraft™CTG-0298, which is resistant to gemcitabine and has a favorable RX-3117 activating enzyme profile. Treatment with RX-3117 resulted in dose dependent TGI and was superior to the standard of care agent gemcitabine. This study successfully demonstrated preliminary efficacy and therapeutic potential of RX-3117. Citation Format: Mi Young Yang, Young Bok Lee, Deog Joong Kim, Chang-Ho Ahn, Joel Kaye, Tania Fine, Rina Kashi, Osnat Ohne. A novel small molecule cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to treatment with gemcitabine. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 819. doi:10.1158/1538-7445.AM2014-819
Androgenesis as a Cause of Hydatidiform Mole 2
Authors: Norio Wake, Nobuo Takagi, Motomichi Sasaki
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article Androgenesis as a Cause of Hydatidiform Mole Get access Norio Wake, Norio Wake 3Chromosome Research Unit, Faculty of Science, Hokkaido University, Sapporo 060, Japan. 4On leave from the Department of Obstetrics and Gynecology, Asahikawa Medical College, Asahikawa, Japan. Search for other works by this author on: Oxford Academic PubMed Google Scholar Nobuo Takagi, Nobuo Takagi 3Chromosome Research Unit, Faculty of Science, Hokkaido University, Sapporo 060, Japan. 5Address reprint requests to Dr. Takagi. Search for other works by this author on: Oxford Academic PubMed Google Scholar Motomichi Sasaki Motomichi Sasaki 3Chromosome Research Unit, Faculty of Science, Hokkaido University, Sapporo 060, Japan. 6We thank Dr. T. Kajii, State University Hospital of the Upstate Medical Center, Syracuse, N.Y., for valuable suggestions and criticisms; and Drs. T. Shimizu, M. Hashimoto, T. Seto, H. Domon, K. Yamashita, Y. Shiina, T. Kanemoto, and T. Yamazaki for their kind cooperation in collecting materials for this study. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 60, Issue 1, January 1978, Pages 51–57, https://doi.org/10.1093/jnci/60.1.51 Published: 01 January 1978 Article history Received: 18 April 1977 Accepted: 29 July 1977 Published: 01 January 1978
Modification of Professional Antigen-Presenting Cells with Small Interfering RNA<i>In vivo</i>to Enhance Cancer Vaccine Potency
Authors: Tae Woo Kim, Jin-Hyup Lee, Liangmei He, David A.K. Boyd, J. Marie Hardwick, Chien-Fu Hung, T-C. Wu
Journal: Cancer Research (2005)

Abstract RNA interference using small interfering RNA (siRNA) is an effective means of silencing gene expression in cells. Intradermal administration of nucleic acids via gene gun represents an efficient method for delivering nucleic acids to professional antigen-presenting cells in vivo. In this study, we show that the coadministration of DNA vaccines encoding human papillomavirus type 16 E7 with siRNA targeting key proapoptotic proteins Bak and Bax prolongs the lives of antigen-expressing dendritic cells in the draining lymph nodes, enhances antigen-specific CD8+ T-cell responses, and elicits potent antitumor effects against an E7-expressing tumor model in vaccinated mice. Our data indicate that intradermal administration of siRNA to manipulate gene expression represents a plausible strategy for modification of the properties of professional antigen-presenting cells in vivo to enhance cancer vaccine potency.
The Conduction of the Nervous Impulse.
Authors: A. L. Hodgkin
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MACROCYTIC ANEMIA IN BANTI'S DISEASE
Authors: D. O. Wright
Journal: Annals of Internal Medicine (1935)

Article1 January 1935MACROCYTIC ANEMIA IN BANTI'S DISEASED. O. WRIGHTD. O. WRIGHTSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-8-7-814 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAn enormous literature has accumulated since Banti first described the three-stage syndrome to which his name has become the eponym. In reviewing countless descriptions that have appeared throughout the years, one finds the almost universal, and at times dogmatic, statement that the accompanying anemia is of the normo- or microcytic type.A case of Banti's disease which shifted while under observation from a microcytic hypochromic type of anemia to one that closely resembled pernicious anemia during remission, has emphasized the fallibility of this statement. The purpose of this communication is to call attention to and suggest a possible explanation for...References1. MUSSERWINTROBE JHMM: Diseases of the blood; in TICE, F.: Practice of medicine, Vol. VI, 1920-1924, W. F. Prior, New York, p. 785. Google Scholar2. WINTROBESHUMACKER MMHS: The occurrence of macrocytic anemia in association with disorder of the liver, Bull. Johns Hopkins Hosp., 1933, lii, 387-407. Google Scholar3. VAN DUYN J: Macrocytic anemia in disease of the liver, Arch. Int. Med., 1933, lii, 839-851. CrossrefGoogle Scholar4. GOLDHAMER SM: Liver extract therapy in cirrhosis of the liver, Arch. Int. Med., 1934, liii, 54-57. CrossrefGoogle Scholar5. SCHULTENMALAMOS HB: Über Veränderungen der roten Blutkorperchen bei Lebererkrankungen, Klin. Wchnschr., 1932, xi, 1338-1339. CrossrefGoogle Scholar6. WRIGHT DO: Macrocytic anemia and hepatic cirrhosis, Am. Jr. Med. Sci. (In press.) Google Scholar7. HANRAHAN EM: Splenic anemia. A study of end-results with and without splenectomy, based on thirty-five cases, Arch. Surg., 1925, x, 639-698. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New Orleans, Louisiana*Received for publication July 9, 1934.From the Department of Medicine, School of Medicine, Tulane University of Louisiana, and the Charity Hospital of Louisiana, New Orleans.†Mean Corpuscular Volume—Volume of packed red cells expressed in cubic centimeters per 1000 c.c. of blood, divided by the number of red cells expressed in millions per cu. mm.; an index of the mean size of red cells, the normal being 75-85 cubic microns.1 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDie Milz als Organ des Pfortadersystems und ihr VersagenErkennung und Behandlung der AnämienMacrocytic anemia in diseases of the liver: General considerations 1 January 1935Volume 8, Issue 7Page: 814-817KeywordsAnemiaBlood cellsCellsHospital medicinePernicious anemia ePublished: 1 December 2008 Issue Published: 1 January 1935 PDF downloadLoading ...
Goldfrank's Toxicologic Emergencies.
Authors: Lewis R. Goldfrank
Journal: Annals of Internal Medicine (1986)

Essential for all emergency physicians, this updated reference presents complete coverage of the clinical management of the poisoned patient. Filled with case studies, the Seventh Edition contains new chapters on Chemical and Biological Terrorism, Sports Toxicology, Forensic Toxicology, and the Development of Drugs.
Atlas of Computed Body Tomography. Normal and Abnormal Anatomy.
Authors: Lee C. Chiu, Rolf L. Schapiro
Journal: Annals of Internal Medicine (1980)

This atlas contains comparative sections on normal and abnormal computed tomography of the neck, chest, abdomen, pelvis, upper and lower limbs, fascia, and peritoneum. Also included is a subject index to aid in the identification of abnormal scans. (DLS)
Abstract P163: Accuracy to Diagnose Cardiac Arrest and Quickness to Start Chest Compression in Different BLS Algorithms; a Comparative Study
Authors: Tomoko Tamura, Koichi Tanigawa, Shinji Kusunoki, Takuma Sadamori, Tadatsugu Otani, Makoto Ishida, Kohei Ota, Satoshi Yamaga, Yoshiko Kida, Ryu Tsumura, Tomohiro Kondo, Taku Takeda, Yasumasa Iwasaki, Nobuyuki Hirohashi
Journal: Circulation (2008)

Background; BLS algorithms for health care providers or experience personnel recommended by AHA, European Resuscitation Council (ERC), and Japanese Resuscitation Council (JPN) differ with respect to the sequence of assessment and procedures. The differences may affect accuracy to diagnose cardiac arrest and quickness to start chest compression. We compared BLS algorithms recommended by these organizations with respect to accuracy of respiratory/circulatory assessment, and quickness to start chest compression using a computed manikin model. Methods; Thirty three subjects (16 physicians and 17 medical students) were enrolled. The Sim-Man (Laerdal) was used to develop 2 scenarios (no pulse/no breathing, with pulse 60/min and breathing 10/min). The three algorithms and 2 scenarios were randomly assigned to the subject, and the accuracy to diagnose cardiac arrest and the time from confirmation of loss of consciousness to starting chest compression were evaluated. Results; The rates of incorrect assessment of respiratory/circulatory status were AHA;9.8% (13 out of 132), ERC;9.1%(12 out of 132) and JPN;6.8%(9 out of 132)(n.s. among algorithms). When the results were analyzed with respect to clinical experiences of the subjects, i.e. physicians vs. medical students, significant differences were found between the groups: AHA;17.2% (11 out of 64), ERC;15.6% (10 out of 64), JPN;12.5% (8 out of 64) in students, whereas AHA;2.9% (2 out of 68), ERC;2.9% (2 out of 68), JPN;1.5% (1 out of 68) in physicians* (* p&lt;0.05 vs. students). The time to starting chest compression were AHA;27.8±5.1 sec, ERC;18.6±3.2** sec, JPN;23.7±4.2 sec (**p&lt;0.05 vs. AHA and JPN), and no significant differences were found between physicians and students. Conclusions; No differences were found in accuracy of respiratory and circulatory assessment among the algorithms, although it may be influenced by clinical experiences of evaluators. The BLS algorithm starting CPR from chest compression such as ERC guidelines may reduce the time of no-flow status in cardiac arrest.